Quest Diagnostics, Inc. (NYSE: DGX) started the day on Wednesday, with a price decrease of -0.22% at $157.12, before settling in for the price of $157.47 at the close. Taking a more long-term approach, DGX posted a 52-week range of $120.87-$159.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 4.86%. Meanwhile, its Annual Earning per share during the time was 7.36%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 2.15%. This publicly-traded company’s shares outstanding now amounts to $111.00 million, simultaneously with a float of $110.77 million. The organization now has a market capitalization sitting at $17.49 billion. At the time of writing, stock’s 50-day Moving Average stood at $152.75, while the 200-day Moving Average is $139.78.
Quest Diagnostics, Inc. (DGX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Diagnostics & Research Industry. Quest Diagnostics, Inc.’s current insider ownership accounts for 0.49%, in contrast to 89.51% institutional ownership. According to the most recent insider trade that took place on Aug 29 ’24, this organization’s SVP & General Counsel sold 32,551 shares at the rate of 154.97, making the entire transaction reach 5,044,516 in total value, affecting insider ownership by 38,478. Preceding that transaction, on Aug 28 ’24, Company’s SVP, Clinical Solutions sold 1,990 for 153.26, making the whole transaction’s value amount to 304,990. This particular insider is now the holder of 11,459 in total.
Quest Diagnostics, Inc. (DGX) Earnings and Revenue Records
Quest Diagnostics, Inc.’s EPS increase for this current 12-month fiscal period is 2.15% and is forecasted to reach 9.70 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 6.85% through the next 5 years, which can be compared against the 7.36% growth it accomplished over the previous five years trading on the market.
Quest Diagnostics, Inc. (NYSE: DGX) Trading Performance Indicators
Let’s observe the current performance indicators for Quest Diagnostics, Inc. (DGX). It’s Quick Ratio in the last reported quarter now stands at 1.17. The Stock has managed to achieve an average true range (ATR) of 3.31. Alongside those numbers, its PE Ratio stands at $21.10, and its Beta score is 0.89. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.83. Similarly, its price to free cash flow for trailing twelve months is now 17.10.
In the same vein, DGX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 7.45, a figure that is expected to reach 2.20 in the next quarter, and analysts are predicting that it will be 9.70 at the market close of one year from today.
Technical Analysis of Quest Diagnostics, Inc. (DGX)
If we take a close look at the recent performances of Quest Diagnostics, Inc. (NYSE: DGX), its last 5-days Average volume was 1.23 million that shows progress from its year to date volume of 0.92 million. During the previous 9 days, stock’s Stochastic %D was recorded 58.26% While, its Average True Range was 3.68.
Raw Stochastic average of Quest Diagnostics, Inc. (DGX) in the period of the previous 100 days is set at 88.48%, which indicates a major rise in contrast to 79.52% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 31.79% that was higher than 21.21% volatility it exhibited in the past 100-days period.
